Stocks Touched New Highs: Ultratech (NASDAQ:UTEK), Landmark Bancorp Inc (NASDAQ:LARK), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Endocyte (NASDAQ:ECYT), NGL Energy Partners LP (NYSE:NGL)

Posted by SQL Server 2016 Developer's Guide on Jun 19, 2014

Stock analysts at Barrington Research started coverage on shares of “Ultratech, Inc.” (NASDAQ:UTEK) in a report issued on Friday, reports. The firm set a “market perform” rating on the stock. Ultratech, Inc. (NASDAQ:UTEK) net profit margin is -26.90% and weekly performance is -7.55%. On last trading day company shares ended up $23.64. Analysts mean target price for the company is $27.60. Ultratech, Inc. (NASDAQ:UTEK) distance from 50-day simple moving average (SMA50) is -7.01%.

Landmark Bancorp (NASDAQ:LARK) Chairman Patrick L. Alexander unloaded 14,224 shares of Landmark Bancorp stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $19.21, for a total transaction of $273,243.04. Following the sale, the chairman now directly owns 99,447 shares in the company, valued at approximately $1,910,377. Landmark Bancorp Inc (NASDAQ:LARK) shares fell -9.79% in last trading session and ended the day on $21.28. LARK return on assets is 0.90%. Landmark Bancorp Inc (NASDAQ:LARK) quarterly performance is 10.14%.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) launched its tender offer for Allergan Inc., taking its roughly $53 billion bid for the Botox maker directly to shareholders. Valeant said on Tuesday that it expected to make the move this week after being rebuffed repeatedly by Allergan’s board. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares moved down -0.37% in last trading session and was closed at $118.43, while trading in range of $117.81 – $120.52. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) year to date (YTD) performance is 0.88%.
Endocyte, Inc. (NASDAQ:ECYT) announced that it has regained worldwide rights to oncology candidate, vintafolide, from Merck & Co. Inc.. Endocyte received the rights to vintafolide as Merck decided to discontinue its investment in the development of vintafolide, after an extensive assessment of Merck’s portfolio. Endocyte, Inc. (NASDAQ:ECYT) ended the last trading day at $6.64. Company weekly volatility is calculated as 6.48% and price to cash ratio as 6.62. Endocyte, Inc. (NASDAQ:ECYT) showed a negative weekly performance of -2.50%.

NGL Energy Partners LP (NYSE:NGL) announced it has priced its underwritten public offering of 8,000,000 common units representing limited partner interests at $43.85 per common unit. NGL also granted the underwriters a 30-day option to purchase up to 1,200,000 additional common units. The offering is expected to close on June 23, 2014, subject to customary closing conditions. NGL intends to use the net proceeds from this offering, including any net proceeds from the underwriters’ exercise of their option to purchase additional common units, to repay indebtedness and for general partnership purposes, including capital expenditures and potential acquisitions. NGL Energy Partners LP (NYSE:NGL) shares moved down -6.94% in last trading session and was closed at $42.50, while trading in range of $42.34 – $43.20. NGL Energy Partners LP (NYSE:NGL) year to date (YTD) performance is 26.87%.


Leave a Reply Don't Date Baptists and Other Warnings from My Alabama Mother

Your email address will not be published. Required fields are marked *